| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Equity issuance costs | NaN | 0 | NaN | NaN |
| Shares issued to ceo for achieving of ip agreement milestones | NaN | 0 | NaN | NaN |
| Loss on settlement of liabilities | NaN | 0 | NaN | NaN |
| Depreciation and amortization | NaN | NaN | 9 | 19 |
| Loss on equity issuance | NaN | 0 | NaN | NaN |
| Discount amortization and interest expenses related to promissory notes | NaN | -5 | 0 | 5 |
| Loss on fixed asset disposal | NaN | -16 | NaN | NaN |
| Loss on warrant repurchase | NaN | NaN | 4 | 95 |
| Issuance of restricted shares as compensation to directors | NaN | 122 | 0 | 0 |
| Linkage difference on principal of loans from stockholders | NaN | 0 | 0 | 0 |
| Net loss | -4,334 | -3,628 | -4,171 | -11,589 |
| Loss on series a warrant repurchase | NaN | 99 | NaN | NaN |
| Depreciation and amortization | 22 | 42 | NaN | NaN |
| Stock-based compensation | 61 | 90 | 41 | 80 |
| Amortization of original issue discount related to promissory note | 148 | 151 | 31 | NaN |
| Change in fair value of derivative liability | 1 | 2 | 0 | -3,269 |
| Increase in other current assets | 1 | 47 | -285 | 371 |
| (decrease) increase in accounts payable | -18 | -392 | -935 | 1,652 |
| Increase in other current liabilities | 75 | -255 | 115 | 157 |
| Net cash used in operating activities | -4,048 | -3,936 | -4,621 | -6,683 |
| Purchase of property and equipment | NaN | 20 | 67 | 9 |
| Net cash used in investment activities | NaN | -20 | -67 | -9 |
| Issuance of convertible promissory notes and bifurcated conversion feature through private placement transaction | NaN | NaN | 0 | NaN |
| Issuance of convertible promissory note, bifurcated conversion and redemption features and detachable warrants through private placement transaction | NaN | NaN | 0 | NaN |
| Net proceeds from exercise of pre-funded warrants | 1 | 0 | 0 | 0 |
| Issuance of convertible promissory notes - related parties | NaN | 0 | NaN | NaN |
| Issuance of convertible promissory notes and bifurcated conversion feature through private placement transaction | NaN | 0 | NaN | NaN |
| Proceeds Received From Underwritten Public Offering | NaN | 0 | NaN | NaN |
| Net | NaN | -50 | 0 | 10,715 |
| Net proceeds from december 2025 private placement transaction | NaN | 3,544 | 0 | 0 |
| Proceeds from promissory note, net of original issue discount of 600 | NaN | 0 | 3,000 | NaN |
| Series a warrant repurchase | NaN | 0 | 6 | 160 |
| Net proceeds from eloc financing | 590 | NaN | NaN | NaN |
| Net cash provided by financing activities | 591 | 3,494 | 2,994 | 10,555 |
| Effect of exchange rate changes on cash and cash equivalents | 3 | -24 | 8 | 65 |
| Change in cash and cash equivalents | -3,454 | -486 | -1,686 | 3,928 |
| Cash and cash equivalents, at beginning of the period | 7,383 | 7,869 | 5,627 | NaN |
| Cash and cash equivalents, end of period | 3,929 | 7,383 | 7,869 | NaN |
Glucotrack, Inc. (GCTK)
Glucotrack, Inc. (GCTK)